Thapsigargin repurposing for COVID-19
Whilst COVID-19 vaccines are being rolled out for mass vaccination, the modest number of antivirals in use or development for
Category: Drug delivery
Clinical trial for Postprandial Responses to ACD-encapsulated Hydroxytyrosol-enriched Bread
The amelioration of postprandial glucose and insulin responses to bread is of great importance since it may have significant beneficial
Hygroscopic measurements on aqueous 2-HP-b-CD droplets as aerosols for drug delivery to the lungs
Despite the interest in CDs as medicinal agents and excipients, the physiochemical properties of CDs and CD derivatives, for example
Roquette on the role of cyclodextrins in vaccines
For vaccine developers, there is intense interest in the critical role of functional excipientsin ensuring the ultimate success of their
CD-based Nanoparticles from CNR-ISMN Institute of Nanostructured Materials
The research group of CNR-ISMN Institute of Nanostructured Materials has developed various CDE-based nanoparticles, nanoassemblies for biomedical applications. Nanoassemblies based
Marinus Pharmaceuticals Receives Positive Response from FDA on Sufficiency of One Phase 3 Clinical Trial for Filing of New Drug Application (NDA) for the Use of SBECD-enabled Ganaxolone in CDKL5 Deficiency Disorder (CDD)
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders,
Dendrimer-based formulation of remdesivir
Current formulations of remdesivir are required to be administered intravenously due to the drug’s low solubility, with each infusion taking
Targetrin Therapeutics, a Cyclolab Ă©s EpiPharma Ăşj közös vállalata ciklodextrin-peptid konjugátumok fejlesztĂ©sĂ©re Ă©s Ă©rtĂ©kesĂtĂ©sĂ©re
A Cyclolab, a ciklodextrin-kutatás, -fejlesztés és -gyártás nagy múltú, világszerte ismert központja valamint az EpiPharma, bio-gyógyszerészeti szolgáltató és peptidegyógyszereket fejlesztő
Cyclolab and EpiPharma Form Joint Venture company Targetrin Therapeutics to Develop and Commercialize novel conjugated Cyclodextrin – Peptide drugs
Cyclolab, the oldest, world renowned cyclodextrin research, development and manufacturing company, and EpiPharma, a bio-pharmaceutical services and peptide drug development
Sedor Pharmaceuticals Receives FDA Approval for SESQUIENT™ (fosphenytoin sodium) for the Treatment of Status Epilepticus in Adult and Pediatric Patients
Sedor Pharmaceuticals, LLC (Sedor) announced on November 9, 2020 that the U.S. Food and Drug Administration (FDA) has approved SESQUIENT